Lexeo Therapeutics (LXEO) Other Operating Expenses (2024 - 2026)

Lexeo Therapeutics has reported Other Operating Expenses for 4 years, with the latest figure at -$4.7 million in Q1 2026.

• Quarterly Other Operating Expenses rose 62.52% year-over-year to -$4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.9 million (up 60.41% YoY) and the FY2025 annual result came in at -$37.0 million, down 48.06% from the prior year.
• Other Operating Expenses slipped to -$4.7 million in Q1 2026 per LXEO's latest filing, from $6.9 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $53.1 million in Q4 2023 and troughed at -$12.6 million in Q1 2025.
• A 4-year average of $264300.0 and a median of -$4.5 million in 2024 frame the typical range for Other Operating Expenses.
• The widest YoY moves for Other Operating Expenses: up 158.39% in 2025, down 209.04% in 2025.
• Over 4 years, Other Operating Expenses stood at $53.1 million in 2023, then sank by 122.21% to -$11.8 million in 2024, then soared by 158.39% to $6.9 million in 2025, then tumbled by 168.35% to -$4.7 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered -$4.7 million, $6.9 million, and -$2.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.